TY - JOUR
T1 - A continuous tri-phase transition effect for HIFU-mediated intravenous drug delivery
AU - Zhang, Kun
AU - Chen, Hangrong
AU - Li, Faqi
AU - Wang, Qi
AU - Zheng, Shuguang
AU - Xu, Huixiong
AU - Ma, Ming
AU - Jia, Xiaoqing
AU - Chen, Yu
AU - Mou, Juan
AU - Wang, Xia
AU - Shi, Jianlin
PY - 2014/7
Y1 - 2014/7
N2 - Aiming at substantially enhanced efficacy and biosafety of clinical HIFU therapy, a natural solid medium, L-menthol (LM), characteristic of mild and controllable "solid-liquid-gas" (SLG) tri-phase transition, was adopted, instead of those conventional explosive liquid-gas (LG) bi-phase transitional media, in constructing a multifunctional theranostic system. Owing to the continuous and controllable characteristics of SLG tri-phase transition, such a novel tri-phase transition-based theranostic system has been demonstrated of the repeatedly enhanced HIFU efficacy exvivo and invivo under once intravenous injection and the significantly improved treatment precision, controllability and biosafety when comparing to the traditional bi-phase transition medium, perfluorohexane (PFH), thus promising great application potential in clinical HIFU treatment. Moreover, this theranostic system has been demonstrated a long blood-circulation lifetime and continuous accumulation in tumor in 24h, which is very beneficial for the enhanced tumor ablation invivo along with SLG tri-phase transition. More importantly, after loading multiple model drugs and real drug, such a theranostic system presents a HIFU-mediated temperature-responsive drug release property, and depending on the versatile miscibility of LM, co-loadings with hydrophobic and hydrophilic drugs are also achieved, which provides the possibility of synergistic treatment combining HIFU therapy and chemotherapy.
AB - Aiming at substantially enhanced efficacy and biosafety of clinical HIFU therapy, a natural solid medium, L-menthol (LM), characteristic of mild and controllable "solid-liquid-gas" (SLG) tri-phase transition, was adopted, instead of those conventional explosive liquid-gas (LG) bi-phase transitional media, in constructing a multifunctional theranostic system. Owing to the continuous and controllable characteristics of SLG tri-phase transition, such a novel tri-phase transition-based theranostic system has been demonstrated of the repeatedly enhanced HIFU efficacy exvivo and invivo under once intravenous injection and the significantly improved treatment precision, controllability and biosafety when comparing to the traditional bi-phase transition medium, perfluorohexane (PFH), thus promising great application potential in clinical HIFU treatment. Moreover, this theranostic system has been demonstrated a long blood-circulation lifetime and continuous accumulation in tumor in 24h, which is very beneficial for the enhanced tumor ablation invivo along with SLG tri-phase transition. More importantly, after loading multiple model drugs and real drug, such a theranostic system presents a HIFU-mediated temperature-responsive drug release property, and depending on the versatile miscibility of LM, co-loadings with hydrophobic and hydrophilic drugs are also achieved, which provides the possibility of synergistic treatment combining HIFU therapy and chemotherapy.
KW - Continuous ultrasound imaging
KW - HIFU-mediated drug delivery
KW - Repeated HIFU treatment
KW - Tri-phase transition
UR - https://www.scopus.com/pages/publications/84899952809
U2 - 10.1016/j.biomaterials.2014.03.043
DO - 10.1016/j.biomaterials.2014.03.043
M3 - 文章
C2 - 24746229
AN - SCOPUS:84899952809
SN - 0142-9612
VL - 35
SP - 5875
EP - 5885
JO - Biomaterials
JF - Biomaterials
IS - 22
ER -